Cargando…

Definitive Cefazolin Treatment for Community-Onset Enterobacteriaceae Bacteremia Based on the Contemporary CLSI Breakpoint: Clinical Experience of a Medical Center in Southern Taiwan

Cefazolin is traditionally active against Escherichia coli, Klebsiella species, and Proteus mirabilis (EKP) isolates. The Clinical and Laboratory Standards Institute (CLSI) has twice updated cefazolin susceptibility breakpoints for EKP since 2010, but its role in the definitive treatment of cefazoli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Ching-Chi, Lee, Chung-Hsun, Chen, Po-Lin, Hsieh, Chih-Chia, Tang, Hung-Jen, Ko, Wen-Chien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963614/ https://www.ncbi.nlm.nih.gov/pubmed/31717641 http://dx.doi.org/10.3390/antibiotics8040216

Ejemplares similares

1599. Clinical Outcomes for Patients Treated with Fluoroquinolones for Bacteremia Caused by Enterobacteriaceae Reclassified as Not Susceptible by Updated CLSI Breakpoints
por: Fleischner, Zachary, et al.
Publicado: (2020)

Definitive Cefazolin Therapy for Stabilized Adults with Community-Onset Escherichia coli, Klebsiella Species, and Proteus mirabilis Bacteremia: MIC Matters
por: Hsieh, Chih-Chia, et al.
Publicado: (2020)

Mortality Impact of CLSI Carbapenem Breakpoint Changes in Enterobacteriaceae Bloodstream Infections: a Patient-level Analysis of Published Data
por: O’Donnell, J Nicholas, et al.
Publicado: (2017)

Clinical Impact of Revised Cefepime Breakpoint in Patients With Enterobacteriaceae Bacteremia
por: Foong, Kap Sum, et al.
Publicado: (2019)

2184. Effect of Adjusted CLSI Breakpoints on Center-wide Fluoroquinolone Susceptibilities for Enterobacteriaceae and Pseudomonas aeruginosa: Is It Time to Restrict Empiric Fluoroquinolone Use?
por: Sansom, Sarah, et al.
Publicado: (2019)

Impact of CLSI and EUCAST breakpoint discrepancies on reporting of antimicrobial susceptibility and AMR surveillance
por: Cusack, T.P., et al.
Publicado: (2019)

Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints
por: Sachu, Arun
Publicado: (2023)

2144. Performance of 2019 CLSI Ciprofloxacin Breakpoint Antimicrobial Susceptibility Testing Algorithms for Enterobacteriaceae and Pseudomonas aeruginosa Directly from Positive Blood Culture on the Accelerate Pheno™ System
por: Shamsheyeva, Alena, et al.
Publicado: (2019)

642. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) Enterobacteriaceae (ENT) from 2016-2019: A Multicenter Evaluation
por: Gupta, Vikas, et al.
Publicado: (2021)

2238. Effect of Cefazolin Breakpoint Update in Susceptibility Reports on Antimicrobial Use
por: Buckley, Valerie, et al.
Publicado: (2023)

Clinical Manifestations of Bacteremia Caused by Aeromonas Species in Southern Taiwan
por: Tang, Hung-Jen, et al.
Publicado: (2014)

Carbapenem-Resistant Enterobacteriaceae Infections: Taiwan Aspects
por: Jean, Shio-Shin, et al.
Publicado: (2018)

1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol
por: Yamano, Yoshinori, et al.
Publicado: (2020)

356. Impact of CLSI Breakpoint Changes on Unit-Specific Combination Antibiograms for Gram-Negative Respiratory Isolates
por: Wangchinda, Walaiporn, et al.
Publicado: (2023)

1072. Streamlining to Oral β-Lactam vs. Fluoroquinolone as Definitive Therapy for Enterobacteriaceae Bacteremia
por: Fong, Karen, et al.
Publicado: (2018)

CLSI announces availability of new CLSI microbiology documents
Publicado: (2007)

Clostridium difficile Bacteremia, Taiwan1
por: Lee, Nan-Yao, et al.
Publicado: (2010)

738. Outcomes of Ceftriaxone Versus Antistaphylococcal Penicillins or Cefazolin for Definitive Therapy of Methicillin-susceptible Staphylococcus aureus Bacteremia
por: Khodadadi, Ryan B, et al.
Publicado: (2022)

Clinical Impact and Risk Factors of Nonsusceptibility to Third-Generation Cephalosporins Among Hospitalized Adults with Monomicrobial Enterobacteriaceae Bacteremia in Southern Taiwan: A Multicenter Study
por: Lin, Tsao-Chin, et al.
Publicado: (2021)

Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination
por: Cagnardi, Petra, et al.
Publicado: (2018)

Appropriateness of Empirical Fluoroquinolones Therapy in Patients Infected with Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa: The Importance of the CLSI Breakpoints Revision
por: Wang, Ying, et al.
Publicado: (2021)

2113. Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

247. Evaluation of the Efficacy and Safety of Cefazolin in Non-Pneumococci Streptococcal Bacteremia
por: Wibisono, Arya, et al.
Publicado: (2023)

230. Multicenter Assessment of the Accuracy of MIC Results for Colistin with MicroScan Dried Gram Negative MIC Panels using CLSI Breakpoints
por: Riedel, Stefan, et al.
Publicado: (2022)

A simple scoring algorithm predicting extended-spectrum β-lactamase producers in adults with community-onset monomicrobial Enterobacteriaceae bacteremia: Matters of frequent emergency department users
por: Lee, Chung-Hsun, et al.
Publicado: (2017)

2813. Impact of a Recent Change in Tobramycin Breakpoints (CLSI) on the Proportion of Pseudomonas aeruginosa Clinical Isolates that are Multidrug-Resistant: CANWARD, 2016 to 2021
por: Walkty, Andrew, et al.
Publicado: (2023)

266. Ceftriaxone Versus Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia
por: Mohamed, Adham, et al.
Publicado: (2020)

Timing of follow-up blood cultures for community-onset bacteremia
por: Lee, Ching-Chi, et al.
Publicado: (2019)

CLSI-Derived Hematology and Biochemistry Reference Intervals for Healthy Adults in Eastern and Southern Africa
por: Karita, Etienne, et al.
Publicado: (2009)

Interpretation of Antimicrobial Susceptibility Testing Using European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) Breakpoints: Analysis of Agreement
por: Gaur, Priyanka, et al.
Publicado: (2023)

Bacteremia Caused by Group G Streptococci, Taiwan
por: Liao, Chun-Hsing, et al.
Publicado: (2008)

Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaxime-resistant Enterobacteriaceae bacteremia
por: Lee, Chen-Hsiang, et al.
Publicado: (2018)

Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia
por: Schweizer, Marin L, et al.
Publicado: (2011)

Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia
por: Sakoulas, George, et al.
Publicado: (2016)

The Cefazolin Inoculum Effect Is Associated With Increased Mortality in Methicillin-Susceptible Staphylococcus aureus Bacteremia
por: Miller, William R, et al.
Publicado: (2018)

1549. Impact of New Fluoroquinolone Breakpoints on Enterobacteriaceae Susceptibility Rates and Clinical Outcomes
por: Pettit, Natasha N, et al.
Publicado: (2019)

Clinical Impact of Revised Ciprofloxacin Breakpoint in Patients with Urinary Tract Infections by Enterobacteriaceae
por: Park, Ga Eun, et al.
Publicado: (2021)

Effect of the 2014 Clinical and Laboratory Standards Institute urine-specific breakpoints on cefazolin susceptibility rates at a community teaching hospital
por: Chastain, Daniel B., et al.
Publicado: (2017)

1597. Evaluation of Ceftaroline Resistance (CPT-R) in Chile Across Time and a Comparison of CLSI vs. EUCAST Breakpoints in Methicillin-Resistant Staphylococcus aureus (MRSA)
por: Khan, Ayesha, et al.
Publicado: (2019)

667. Multicenter Assessment of Enterobacterales, Salmonella spp. and Pseudomonas aeruginosa Using Updated CLSI Levofloxacin Breakpoints on MicroScan Dried Gram Negative MIC Panels
por: Garner, Omai, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p7b3t21i86n1884j6qc6qca0u5